A lower eGFRcystatin C/eGFRcreatinine ratio is associated with greater cardiovascular risk (higher Framingham Risk Score) in Chinese patients with newly diagnosed type 2 diabetes mellitus
Yan Yang,
Bixia Yang,
Shizhu Zhao,
Shusu Liu,
Hua Zhou,
Ning Xu,
Min Yang
Affiliations
Yan Yang
Department of Nephrology, The Third Affiliated Hospital of Soochow University, Changzhou, China
Bixia Yang
Department of Nephrology, The Third Affiliated Hospital of Soochow University, Changzhou, China
Shizhu Zhao
Department of Nephrology, The Third Affiliated Hospital of Soochow University, Changzhou, China
Shusu Liu
Department of Nephrology, The Third Affiliated Hospital of Soochow University, Changzhou, China
Hua Zhou
Department of Nephrology, The Third Affiliated Hospital of Soochow University, Changzhou, China
Ning Xu
Division of Clinical Chemistry and Pharmacology, Department of Laboratory Medicine, Lund University, Lund, Sweden
Min Yang
Department of Nephrology, The Third Affiliated Hospital of Soochow University, Changzhou, China
Background Cardiovascular disease (CVD) is the leading cause of mortality in type 2 diabetes mellitus (T2DM) patients. Shrunken pore syndrome (SPS) is defined as eGFRcystatin C/eGFRcreatinine ratio 0.85, eGFRcystatin C/eGFRcreatinine≤0.85 increased FRS risk (OR = 1.95, 95%CI = 1.18–3.21, p 0.85 (OR = 1.86, 95%CI = 1.08–3.21, p = 0.03).Conclusions In the current study, no significant association between SPS and FRS was identified. However, lower eGFRcystatin C/eGFRcreatinine and eGFRcystatin C/eGFRcreatinine≤0.85 were associated with a significantly increased CVD risk in T2DM.
